Magenta Therapeutics, Inc. Gains 16.14%
Thu, Jan 06, 2022 at 05:30 PM
Magenta Therapeutics, Inc. (MGTA:NASDAQ) soared at $5.18, representing a gain of 16.1%. On Wed, Jan 05, 2022, MGTA:NASDAQ touched a New 2-Week Intraday Low of $4.42. The stock appeared on our News Catalysts scanner on Wed, Jan 05, 2022 at 09:39 AM in the 'MISCELLANEOUS' category. From Wed, Dec 22, 2021, the stock recorded 33.33% Up Days and 30.00% Green Days
About Magenta Therapeutics, Inc. (MGTA:NASDAQ)
Magenta Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing novel medicines to bring the curative power of bone marrow transplant.
Top 10 Gainers:
- EAR (EAR:NASDAQ), 59.65%
- Alterity Therapeutics Limited (ATHE:NASDAQ), 33.82%
- China Natural Resources, Inc. (CHNR:NASDAQ), 27.79%
- Vocera Communications, Inc. (VCRA:NYSE), 26.63%
- NBTX (NBTX:NASDAQ), 22.21%
- IMAC Holdings, Inc. (IMAC:NASDAQ), 21.05%
- AgeX Therapeutics, Inc. (AGE:NYSEMKT), 20.05%
- Phunware, Inc. (PHUN:NASDAQ), 19.92%
- ENSC (ENSC:NASDAQ), 18.16%
- Magenta Therapeutics, Inc. (MGTA:NASDAQ), 16.14%